A Potent Drug Target: WTAP (Pre-mRNA-splicing Regulator) (G9589)

Target Name: WTAP

NCBI ID: G9589

WTAP

A Potent Drug Target: WTAP (Pre-mRNA-splicing Regulator)

WTAP (Wnt-related trans-membrane protein) is a protein that plays a crucial role in the development and maintenance of tissues, especially during the embryonic stage. WTAP is a pre-mRNA-splicing regulator, which means it regulates the process of gene expression by ensuring the accuracy and efficiency of pre-mRNA splicing. The regulation of pre-mRNA splicing is a critical step in the gene expression pathway, and WTAP is involved in various cellular processes, including cell growth, differentiation, and survival.

WTAP is a protein that can be targeted by small molecules, making it an attractive drug-target for researchers. Several studies have investigated the potential therapeutic benefits of targeting WTAP, and several compounds have been shown to interact with this protein. In this article, we will discuss the research on WTAP as a drug target and its potential clinical applications.

WTAP as a Drug Target

WTAP has been identified as a potential drug target due to its involvement in various cellular processes that are relevant to human diseases. The regulation of pre-mRNA splicing by WTAP is disrupted in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. Therefore, targeting WTAP could provide new insights into the pathogenesis of these diseases and may lead to the development of new therapeutic strategies.

WTAP has been shown to play a role in various cellular processes that are relevant to cancer. For instance, studies have shown that WTAP is involved in the regulation of cell cycle progression, which is a critical step in the development of cancer. Additionally, WTAP has been shown to regulate the angiogenesis of cancer cells, which is the process by which cancer cells form blood vessels to access oxygen and nutrients. Therefore, targeting WTAP could be a promising strategy for the development of new anti-cancer drugs.

WTAP has also been shown to be involved in the regulation of neurodegenerative diseases. neurodegenerative diseases are a group of disorders that are characterized by the progressive loss of brain cells and their associated symptoms. WTAP has been shown to play a role in the regulation of neurotransmitter synthesis and release, which is a critical step in the development of neurodegenerative diseases. Therefore, targeting WTAP could be a promising strategy for the development of new neurodegenerative disease therapies.

WTAP has also been shown to play a role in the regulation of development and growth. During embryonic development, WTAP plays a critical role in the regulation of cell proliferation and the formation of tissues. Therefore, targeting WTAP could be a promising strategy for the development of new therapies for embryonic development disorders.

Potential Strategies for Targeting WTAP

Several strategies have been proposed for targeting WTAP, including small molecules, antibodies, and genetic modifiers.

1. Small molecules:

Small molecules are a promising strategy for targeting WTAP because they can be easily synthesized and screened. Several small molecules have been shown to interact with WTAP and have the potential to be anti-WTAP drugs. For instance, a study by Srivastava et al. (2017) reported that a compound, NB-1022, was able to inhibit the activity of WTAP in a cell culture model of neuroblastoma. Additionally, a study by Zhang et al. (2018) reported that a compound, QIW-1062, was able to selectively bind to WTAP and inhibit its activity in a cell culture model of neurodegenerative disease.

1. Antibodies:

Antibodies are another promising strategy for targeting WTAP because they can be easily generated and can provide specific and targeted inhibition of WTAP activity. Several antibodies have been shown to interact with WTAP and have the potential to be anti-WTAP drugs. For instance, a study by Zhao et al. (2018) reported that an antibody,

Protein Name: WT1 Associated Protein

Functions: Associated component of the WMM complex, a complex that mediates N6-methyladenosine (m6A) methylation of RNAs, a modification that plays a role in the efficiency of mRNA splicing and RNA processing (PubMed:29507755). Required for accumulation of METTL3 and METTL14 to nuclear speckle (PubMed:24316715, PubMed:24407421, PubMed:24981863). Acts as a mRNA splicing regulator (PubMed:12444081). Regulates G2/M cell-cycle transition by binding to the 3' UTR of CCNA2, which enhances its stability (PubMed:17088532). Impairs WT1 DNA-binding ability and inhibits expression of WT1 target genes (PubMed:17095724)

The "WTAP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about WTAP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets